InVentiv Health, INC Research merger creates top 3 CRO

The newly formed company carries a $7.4 billion valuation, and will employ more than 22,000 people worldwide.

By Jacob Bell • May 11, 2017

Pfizer taps Sangamo for hemophilia gene therapy

The deal validates Sangamo's gene therapy technology and provides Pfizer with another gene therapy in the hemophilia space. 

By Lisa LaMotta • May 11, 2017

New partnership will advance novel platform for I/O

Takeda and GammaDelta Therapeutics will collaborate to develop a T-cell platform for use in cancer and auto-inflammatory disease treatments.    

By Barbara Boughton • May 10, 2017

Allergan defends threatened franchises, but says 'no large M&A'

The company is banking on a handful of mid- and late-stage candidates, as well as continued M&A, to be a safeguard against threats to legacy products.

By Jacob Bell • May 9, 2017

Novartis pushes further into pain with Durect deal

The massive medicines maker continued to flesh out its pain drug pipeline on Monday, inking a new agreement that could be worth around $300 million.

By Jacob Bell • May 8, 2017

Prescribed Reading: Deals to come, but when?

Pfizer and Gilead could be in a deal-making mood, while the FDA continues to approved drugs at a rapid clip and clinical failures keep coming. 

By Lisa LaMotta • May 5, 2017

Novartis picks up option for Conatus NASH drug

Just five months after inking the original deal, Novartis has signed on the dotted line to move forward with Conatus' emricasan.

By Suzanne Elvidge • May 5, 2017

Gilead finally ready to make a deal?

The big biotech may finally be able to make some deals that could help its declining hepatitis C sales.

By Lisa LaMotta • May 3, 2017

Pieris teams up with AstraZeneca on respiratory drug development

The collaboration with the British pharma is Pieris' second alliance signed this year, part of a push to accelerate development of the biotech's platform technology.

By Ned Pagliarulo • May 3, 2017

Pfizer hints a Bristol deal is on the table

Focus was squarely on the big pharma's business development strategy, despite somewhat disappointing earnings in the first quarter.

By Lisa LaMotta • May 2, 2017

Shire commits up to $535M for Parion's dry eye drug

Looking to expand its ophthalmic offerings, the Irish pharma announced it is adding a new mid-stage candidate to its pipeline.

By Jacob Bell • May 1, 2017

Q1 Earnings Preview: Gilead, Merck, Pfizer, Allergan

Tuesday is expected to be another busy days for earnings reports, with Pfizer and big biotechs like Gilead announcing financial performance for the first quarter. 

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • May 1, 2017

Prescribed Reading: Rough start for pharma, but optimism abounds

First quarter earnings were not particularly strong, but there were several bright spots; Gottlieb confirmation rolls forward; and The Medicines Co. lays down cash for its CV outcomes trial.

By Lisa LaMotta • April 28, 2017

Amgen, Novartis tweak partnership on migraine drug

The companies are readying a regulatory submission for erenumab, one of several CGRP inhibitors nearing the market for prevention of migraine. 

By Suzanne Elvidge • April 26, 2017

Capitalize on your merger/acquisition: 4 tips to consolidate your CMO network

Establish measurable objectives, set criteria for CMO evaluation, outline geographic requirements, and rationalize your portfolio to improve outcomes in network consolidation.

April 25, 2017

Fresenius Kabi picks up generic maker Akorn for $4.3B

A deal between the German company's U.S. subsidiary and the specialty generic drugmaker is a logical fit, analysts say. 

By Lisa LaMotta • April 25, 2017

Prescribed Reading: What J&J says about the rest of pharma

J&J earnings predict a rough first quarter for big pharma, AbbVie has a bad week, and Lilly's surprise rejection is great news for Pfizer. 

By Lisa LaMotta • April 21, 2017

Former Dendreon CEO debuts new public company in reverse merger

Alpine Immune Sciences will merge with a subsidiary of Nivalis Therapeutics, which had been searching for a way forward after a clinical failure. 

By Ned Pagliarulo • April 19, 2017

Allergan, Novartis ink NASH partnership

The deal will pair Allergan's drug cenicriviroc and Novartis' candidate LJN452 in a Phase 2b study of patients with the liver disease.

By Jacob Bell • April 18, 2017

Amarantus creates spinouts in restructuring

The biotech is keeping its eye on the future with spinouts in ophthalmology and CNS disorders.

By Suzanne Elvidge • April 18, 2017

Bristol-Myers taps Danish biotech in NASH biomarker deal

The partnership with Nordic Bioscience reflects the challenges of accurately diagnosing NASH, sometimes termed a "silent" disease. 

By Ned Pagliarulo • April 17, 2017

Biogen, Roche ink deals with Bristol for rare disease drugs

Biogen is licensing a potential Alzheimer's treatment, Roche is getting rights to a DMD drug and Bristol-Myers Squibb is pocketing money for other projects.

By Jacob Bell • April 13, 2017

Biopharma IPOs sluggish in Q1. Will that continue?

With venture funding leveling off and just four IPOs in the first quarter, industry followers aren't expecting a record-breaking year for private biopharma exits.

By Jacob Bell • April 13, 2017

Could organs on a microchip help test for toxins? The FDA wants to find out

The regulator will collaborate with the private Emulate, Inc. to test the company's organ-on-a-chip technology as a potential toxicology testing platform.

By Suzanne Elvidge • April 13, 2017

SV Health secures $400M for new life sciences venture fund

Although biotech IPO activity remains weak, investors are still showing a willingness to pour fresh money into early-stage companies. 

By Ned Pagliarulo • April 12, 2017